camptothecin has been researched along with sirolimus in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (29.63) | 29.6817 |
| 2010's | 19 (70.37) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Bubley, GJ; Jones, GB; Torregrossa, J | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Batista-Gonzalez, A; Brunhofer, G; Fallarero, A; Gopi Mohan, C; Karlsson, D; Shinde, P; Vuorela, P | 1 |
| Liu, Y; Xu, Z; Zhao, SJ | 1 |
| Cotter, TG; Knox, KA; McGahon, AJ; McKenna, SL; O'Gorman, DM | 1 |
| Fung, KM; Geoerger, B; Janss, AJ; Kerr, K; Phillips, PC; Powell, B; Sutton, LN; Tang, CB | 1 |
| Borner, MM | 1 |
| Cohen, RB; Dahlberg, S; Hidalgo, M; Johnson, DH; Lee, MW; Pandya, KJ; Schiller, JH | 1 |
| Gaub, MP; Guenot, D; Guérin, E; Larsen, AK; Lelong-Rebel, I; Nicolet, C; Oudet, P; Pencreach, E; Voegeli, AC | 1 |
| Chauffert, B; Ghiringhelli, F; Guiu, B; Ladoire, S | 1 |
| Mehta, SP | 1 |
| Aoyama, M; Asai, K; Ebi, M; Hirata, Y; Joh, T; Kamiya, T; Kataoka, H; Kubota, E; Mizoshita, T; Mori, Y; Murakami, K; Okamoto, Y; Shimura, T; Tanaka, M; Tanida, S | 1 |
| Bowyer, C; Forster, RE; Lewis, AL; Lloyd, AW; Macfarlane, W; Phillips, GJ; Tang, Y | 1 |
| Iwase, Y; Maitani, Y | 1 |
| Boukouris, AE; Buitrago-Molina, LE; Hegermann, J; Kirstein, MM; Kühnel, F; Manns, MP; Marhenke, S; Orlik, J; Pothiraju, D; Schütt, J; Vogel, A | 1 |
| Andersen, RF; Havelund, BM; Jakobsen, AK; Lassen, U; Pallisgaard, N; Ploen, J; Sorensen, MM; Spindler, KL | 1 |
| Bradshaw-Pierce, EL; Eckhardt, SG; Gustafson, DL; Kulikowski, G; Merz, AL; Pitts, TM; Selby, H; Serkova, NJ; Weekes, CD | 1 |
| Arrowsmith, ER; Bajetta, E; Del Prete, SA; Fuchs, CS; Hwang, J; Jin, J; Malek, K; Ng, K; Ryan, DP; Sedova, M; Sharma, S; Tabernero, J | 1 |
| Adamson, PC; Ahern, C; Bagatell, R; Blaney, S; Fox, E; Ingle, AM; Little, AR; Norris, R; Voss, S; Weigel, BJ | 1 |
| Hamasaki, T; Hisamatsu, T; Kawano, M; Kimura, T; Kishimoto, T; Mabuchi, S; Matsumoto, Y; Sasano, T; Sawada, K; Takahashi, K; Takahashi, R; Takahashi, T | 1 |
| Corbacioglu, S; Debatin, KM; Engelke, J; Fulda, S; Halatsch, ME; Karpel-Massler, G; Nonnenmacher, L; Simmet, T; Westhoff, MA | 1 |
| Denning, G; Doering, CB; Johnston, JM; Le Doux, JM; Moot, R; Shields, J; Spencer, HT; Whitehead, D | 1 |
| Gil-Ranedo, J; Mendiburu-Eliçabe, M | 1 |
| Beck, JT; Brandt, U; Davidson, SJ; Garrett, CR; Hecht, JR; Mackenzie, MJ; Reid, TR; Rizvi, S; Sharma, S | 1 |
| Abraham, WD; Bustamante López, SC; Huang, B; Irvine, DJ; Luo, SS; Zheng, Y | 1 |
| Duan, J; Liu, Q; Mu, H; Niu, H; Tang, J; Wang, D | 1 |
3 review(s) available for camptothecin and sirolimus
| Article | Year |
|---|---|
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Triazoles | 2019 |
[Molecular targets in colon cancer].
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Camptothecin; Cetuximab; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Indoles; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Phthalazines; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolones; Receptors, Platelet-Derived Growth Factor; Receptors, Somatomedin; Signal Transduction; Sirolimus; Sunitinib | 2006 |
Palliative chemotherapy for pancreatic malignancies.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Immunosuppressive Agents; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Quality of Life; Quinazolines; Sirolimus | 2010 |
5 trial(s) available for camptothecin and sirolimus
| Article | Year |
|---|---|
A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500)
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Remission Induction; Sirolimus; Survival Rate; Treatment Outcome | 2007 |
Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: outcome and results of KRAS mutational analysis in plasma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Mutation; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Sirolimus; Treatment Outcome | 2013 |
Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Phosphatidylinositol 3-Kinases; Prospective Studies; Proto-Oncogene Proteins B-raf; Pyrimidines; Sirolimus; Treatment Outcome | 2013 |
Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Dacarbazine; Female; Follow-Up Studies; Humans; Infant; Irinotecan; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasms; Prognosis; Remission Induction; Sirolimus; Temozolomide; Young Adult | 2014 |
Phase I study of everolimus, cetuximab and irinotecan as second-line therapy in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Everolimus; Female; Humans; Irinotecan; Male; Middle Aged; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Sirolimus | 2015 |
19 other study(ies) available for camptothecin and sirolimus
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Microwave expedited synthesis of 5-aminocamptothecin analogs: Inhibitors of hypoxia inducible factor HIF-1alpha.
Topics: Camptothecin; Cell Line; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Microwaves; Molecular Structure; Structure-Activity Relationship | 2006 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Humans; Isoquinolines; Kinetics; Molecular Docking Simulation; Structure-Activity Relationship | 2012 |
Sensitisation of HL60 human leukaemic cells to cytotoxic drug-induced apoptosis by inhibition of PI3-kinase survival signals.
Topics: Androstadienes; Antineoplastic Agents; Apigenin; Apoptosis; bcl-Associated Death Protein; bcl-X Protein; Camptothecin; Carrier Proteins; Cell Survival; Chromones; Cycloheximide; Dactinomycin; Dimerization; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Flavonoids; Genes, bcl-2; HL-60 Cells; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Mitoxantrone; Morpholines; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Sirolimus; Wortmannin | 2000 |
Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cell Division; Cisplatin; Drug Synergism; Female; Glioma; Growth Inhibitors; Humans; Medulloblastoma; Mice; Mice, Nude; Neuroectodermal Tumors, Primitive; Sirolimus; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Glycolysis; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Irinotecan; Male; MAP Kinase Signaling System; Mice; Phosphatidylinositol 3-Kinases; Protein Kinases; Proto-Oncogene Proteins c-akt; Sirolimus; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2009 |
Sirolimus, bevacizumab, 5-Fluorouracil and irinotecan for advanced colorectal cancer: a pilot study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Pilot Projects; Sirolimus; Treatment Outcome | 2009 |
ERas enhances resistance to CPT-11 in gastric cancer.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Embryonic Stem Cells; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Irinotecan; Models, Biological; NF-kappa B; Protein Binding; ras Proteins; Sirolimus; Stomach Neoplasms; Up-Regulation | 2011 |
Development of a combination drug-eluting bead: towards enhanced efficacy for locoregional tumour therapies.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Doxorubicin; Humans; Irinotecan; Liver Neoplasms; Mice; Mice, Nude; Pancreatic Neoplasms; Prostheses and Implants; Sirolimus; Topotecan; Xenograft Model Antitumor Assays | 2012 |
Preparation and in vivo evaluation of liposomal everolimus for lung carcinoma and thyroid carcinoma.
Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Cell Survival; Everolimus; Female; Humans; Immunosuppressive Agents; Irinotecan; Liposomes; Lung Neoplasms; Mice; Mice, Inbred BALB C; Sirolimus; Thyroid Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma.
Topics: Aminopyridines; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Camptothecin; Carcinoma, Hepatocellular; Cell Cycle; Cell Line; Cell Respiration; Cisplatin; Doxorubicin; Everolimus; Humans; Imidazoles; Immunoblotting; Immunohistochemistry; In Situ Nick-End Labeling; Irinotecan; Liver Neoplasms; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Quinolines; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Colonic Neoplasms; Drug Synergism; Everolimus; Female; Humans; Immunosuppressive Agents; Irinotecan; Metabolome; Mice; Mice, Nude; Mutation; Neoplasm Transplantation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Sirolimus; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2013 |
Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Proliferation; Cisplatin; Dioxoles; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Everolimus; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Sirolimus; Tetrahydroisoquinolines; Topotecan; Trabectedin; Tumor Cells, Cultured | 2014 |
RIST: a potent new combination therapy for glioblastoma.
Topics: Adolescent; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Child; Dacarbazine; Female; Glioblastoma; Humans; Indoles; Irinotecan; Male; Membrane Potential, Mitochondrial; Mice, Inbred NOD; Molecular Targeted Therapy; Pyrroles; Sirolimus; Sunitinib; Temozolomide; Xenograft Model Antitumor Assays | 2015 |
High-throughput screening identifies compounds that enhance lentiviral transduction.
Topics: Animals; Antigens, CD34; Camptothecin; Cell Line, Tumor; Colforsin; Genetic Therapy; Genetic Vectors; Green Fluorescent Proteins; HEK293 Cells; Hematopoietic Stem Cells; High-Throughput Screening Assays; Humans; Lentivirus; Mice; NIH 3T3 Cells; Sirolimus; Tetradecanoylphorbol Acetate; Transduction, Genetic; U937 Cells | 2014 |
Combination Therapy of Intraperitoneal Rapamycin and Convection- Enhanced Delivery of Nanoliposomal CPT-11 in Rodent Orthotopic Brain Tumor Xenografts.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Drug Monitoring; Glioblastoma; Humans; Infusions, Parenteral; Irinotecan; Liposomes; Rats; Sirolimus; Topoisomerase I Inhibitors; TOR Serine-Threonine Kinases; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells.
Topics: Animals; Antineoplastic Agents; Bystander Effect; Camptothecin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cytotoxicity, Immunologic; Drug Delivery Systems; Humans; Interleukin-2; Irinotecan; Lymph Nodes; Lymphoma; Mice; Nanocapsules; Nanoparticles; Receptors, Lymphocyte Homing; Sirolimus; T-Lymphocytes; Treatment Outcome | 2015 |
Autophagy promotes DNA-protein crosslink clearance.
Topics: Adenine; Animals; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 5; Autophagy-Related Protein 7; Camptothecin; Cell Line, Tumor; Cell Survival; Chloroquine; DNA Damage; Formaldehyde; Gene Silencing; Humans; Mice; Mice, Inbred C57BL; Microtubule-Associated Proteins; RNA, Small Interfering; Sirolimus; Ubiquitin-Activating Enzymes; Ultraviolet Rays | 2016 |